Hims & Hers Q1 2026 Earnings: How the Telehealth Giant Is Pivoting Toward Profitability

Hims & Hers Health (HIMS) delivered mixed but strategic results in its first quarter of 2026, signaling a deliberate shift toward profitability through branded weight loss products, international expansion, and operational efficiency. With revenue up 4% year-over-year to $608 million and subscriber growth of 9%, the company raised its full-year guidance—demonstrating confidence in its pivot away from unprofitable growth toward sustainable margins.

Steady Revenue Growth Amid Strategic Shifts

Hims & Hers reported Q1 2026 revenue of $608 million, marking a 4% year-over-year increase—a modest but stable performance in a crowded telehealth market. The company attributed its growth to a diversified product portfolio, including testosterone therapy, erectile dysfunction treatments, and—most critically—weight loss solutions.

Subscriber growth remained robust, with the company adding 9% more subscribers year-over-year, bringing the total to nearly 2.6 million. This growth underscores the company’s ability to retain and attract users, particularly in its core men’s health segments.

However, the most striking metric was the 980% year-over-year increase in international revenue, which reached $78 million. This surge was driven by the acquisitions of ZAVA (UK-based telehealth) and LIVWELL (Asia-focused weight management), positioning Hims & Hers as a global player in digital health.

“Our international expansion is accelerating faster than we anticipated. The ZAVA and LIVWELL acquisitions have given us a foothold in Europe and Asia, where demand for digital health solutions is exploding.”

Profitability Improves as Marketing Spend Drops

Despite a $92 million GAAP net loss—primarily due to $33 million in restructuring charges—Hims & Hers demonstrated progress in profitability. Adjusted EBITDA reached $44 million, representing a 7% margin, a significant improvement from prior quarters.

The company’s gross margin stood at 65% on a GAAP basis and 70% adjusted, excluding one-time costs. This efficiency was further highlighted by a 36% reduction in marketing spend as a percentage of revenue, down from 39% in the prior year—a testament to the company’s focus on sustainable growth.

Cash flow remained strong, with $89 million in operating cash flow and $53 million in free cash flow generated in the quarter. The company ended Q1 with $751 million in cash and short-term investments, providing ample liquidity for future investments.

Wegovy Launch Drives Weight Loss Subscribers

The most significant driver of Hims & Hers’ growth in Q1 was its branded weight loss initiative, centered around the launch of Wegovy, a GLP-1 receptor agonist approved for chronic weight management. Within just six weeks of launch, the company fulfilled over 125,000 Wegovy shipments, a remarkable adoption rate for a new product in a highly competitive market.

New weight loss subscribers are now being added at a rate of over 100,000 per month, a pace that suggests the company is capturing a meaningful share of the $30 billion global weight loss market. Customer engagement data further reinforces this momentum:

• 90% of new weight loss subscribers downloaded the Hims & Hers app.
• The average subscriber interacted with a healthcare provider three times in their first month.
• 95% of testosterone therapy users achieved increased testosterone levels within two months of starting treatment.

This data indicates that Hims & Hers is not only attracting users but also driving high engagement—a critical factor in subscription retention and long-term profitability.

Full-Year 2026 Guidance Raised: A Bigger Bet on Weight Loss and International Growth

Confident in its execution, Hims & Hers raised its full-year revenue outlook to $2.8 billion–$3.0 billion, representing a 19%–28% year-over-year increase. The company also projected adjusted EBITDA of $275 million–$350 million, translating to an 11% margin at the midpoint—a significant leap from its current trajectory.

This guidance reflects the company’s strategic priorities:

• Weight Loss Dominance: Wegovy and other GLP-1 therapies are expected to become the company’s highest-growth segment.
• International Expansion: ZAVA and LIVWELL will continue driving revenue growth in Europe and Asia.
• Operational Efficiency: Further reductions in marketing spend and cost optimization will improve margins.

The company also announced that it has $225 million remaining in share repurchase authorization, signaling confidence in its stock valuation and a commitment to returning value to shareholders.

Key Risks to Watch

While Hims & Hers’ outlook is optimistic, several risks could impact its trajectory:

1. Regulatory Scrutiny: The weight loss market, particularly GLP-1 therapies, faces increasing regulatory and reimbursement challenges.
2. Competition: Rivals like Nouvelle and Caru Health are also expanding in telehealth and weight loss.
3. Macroeconomic Pressures: Rising interest rates and inflation could impact consumer spending on discretionary healthcare services.
4. Integration Risks: Successfully merging ZAVA and LIVWELL into Hims & Hers’ operations will be critical to sustaining international growth.

FAQ: Hims & Hers Q1 2026 Earnings

Why did Hims & Hers report a net loss despite revenue growth?

The company reported a $92 million GAAP net loss primarily due to $33 million in restructuring charges. However, adjusted EBITDA was positive at $44 million, indicating underlying profitability.

How is Wegovy performing for Hims & Hers?

Wegovy has been a major success, with over 125,000 shipments fulfilled in six weeks and new weight loss subscribers being added at a rate of over 100,000 per month.

What is driving Hims & Hers’ international growth?

The acquisitions of ZAVA (UK) and LIVWELL (Asia) have accelerated international revenue growth, which surged nearly 10x year-over-year to $78 million.

What is Hims & Hers’ full-year 2026 revenue guidance?

The company raised its full-year revenue outlook to $2.8 billion–$3.0 billion, a 19%–28% increase year-over-year.

Bottom Line: A Pivot Toward Profitability

Hims & Hers’ Q1 2026 earnings reflect a company in transition—shifting from rapid, unprofitable growth to a more sustainable, margin-focused model. The success of Wegovy, international expansion, and operational efficiency are positioning the company for long-term profitability.

While challenges remain—particularly in regulation, competition, and macroeconomic conditions—the company’s strategic pivots suggest it is well-positioned to capitalize on the growing digital health market. Investors and observers should watch closely as Hims & Hers executes on its weight loss and international growth strategies in the coming quarters.

For now, the message is clear: Hims & Hers is no longer just a men’s health startup—it’s a diversified, globally expanding healthcare platform with a clear path to profitability.